STUDY QUESTION: Can controlled ovarian hyperstimulation (COH) for fertility preservation be effectively conducted in women with breast cancer without worsening their prognosis?
Introduction
Breast cancer is the most commonly diagnosed cancer in women, with 1.67 million new cases of breast cancer diagnosed worldwide in 2012 (WHO, 2012a,b) . One in five of these women is <45 years of age at diagnosis (WHO, 2012a,b) , and with substantial improvements in cancer treatment (the overall 5-year survival rate in women with breast cancer has increased from 74.6% in 1975-1979 to 91.0% in 2007 in the USA; National Institute of Cancer, 2015) , fertility preservation has become an increasingly important issue for women with breast cancer (Partridge et al., 2004 (Partridge et al., , 2008 Azvolinsky, 2012; Ruddy et al., 2014; Ganz et al., 2015) .
Fertility preservation is complex since breast cancer is often oestrogen sensitive and the supra-physiological oestradiol levels generated during controlled ovarian hyperstimulation (COH) could result in the proliferation of breast cancer cells. Standard COH protocols result in greatly elevated oestradiol concentrations-from a peak concentration of around 300 pg/ml in a natural cycle (Fahy et al., 1995) to 456-6 957 pg/ml during COH (Asch et al., 1991; Morris et al., 1995; Mitwally et al., 2006; Wu et al., 2007; Bianco et al., 2009; Moraloglu et al., 2012; Huang et al., 2014; Pereira et al., 2015) .
Modifications to standard COH protocols have been made in an attempt to reduce potential harm associated with raised oestradiol levels. Two common agents used for this purpose are aromatase inhibitors (AIs) that block the catalytic conversion of androstenedione to oestrone, and testosterone to oestradiol, and selective oestrogen receptor modulators, such as tamoxifen, that bind to the oestrogen receptor, inducing a conformational change and facilitating or suppressing the transcription of target genes (Shelly et al., 2008) .
This systematic review analyse the available data pertaining to the safety and efficacy of COH for fertility preservation in women with early breast cancer. The primary outcome of mortality/recurrence in women having COH is presented, and important secondary outcomes of peak oestradiol concentration, oocyte yield and treatment complications are analysed.
Materials and Methods

Search strategy and study selection
The study population was premenopausal women diagnosed with Stage I-IIIB breast cancer who underwent COH in the immediate post-operative period, prior to the administration of chemotherapy. All COH protocols were included despite the higher risk of bias in non-randomized studies as it is not possible to randomize women into fertility preservation studies comparing COH with placebo administration. Studies reporting the primary outcome of breast cancer mortality or recurrence and secondary outcomes of peak oestradiol levels during COH, oocyte yield and treatment-related complications were included.
Relevant studies were identified from MEDLINE, EMBASE and the Cochrane Library. The MEDLINE database was searched using the following search criteria: 'breast neoplasms' [MeSH] AND 'reproductive techniques' [MeSH] and English [lang] . The EMBASE search strategy consisted of: Breast cancer AND fertility preservation OR ovary hyperstimulation OR ovulation induction OR superovulation OR controlled ovarian hyperstimulation AND English language. The Cochrane database search consisted of: 'breast neoplasms' [MeSH] AND 'reproductive techniques' [MeSH] . The search was restricted to articles written in English. No restrictions regarding the date of publication were applied. The search was last updated in April 2016. The electronic search was complimented by a manual search of bibliographies.
Two reviewers (R.R. and G.R.) independently conducted a search of the literature and selected relevant studies. Titles and abstracts of all studies identified were examined to assess their relevance. The full text was obtained for all relevant studies. If the reviewers were uncertain regarding the suitability of the article, consensus was reached after discussion with additional reviewers (J.A. and J.K.). The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement (Moher et al., 2009 ) was used as the basis for critical appraisal of the studies.
The studies included in this review report oestradiol concentrations in gravimetric units (pg/ml). In order to convert to standard international units (pmol/l), a conversion factor of 3.67 should be used.
Results
The search identified 933 unique citations for screening, with the evaluation and selection process outlined in Fig. 1 .
Of the 15 selected studies, 12 involved the administration of letrozole and 4 involved the administration of tamoxifen, with 1 study evaluating both medications. One paper compared letrozole and anastrozole (Azim et al., 2007) . Two studies compared GnRH agonist and hCG triggers Reddy et al., 2014) .
The studies included comprised 1 516 women of whom 991 had a recent diagnosis of Stage 0-IIIB breast cancer and elected to have COH for fertility preservation. The remaining 525 women acted as controls. Of women with breast cancer undergoing COH, 882 received letrozole, 102 received tamoxifen and 7 received anastrozole co-administration. No studies performed COH in women with an oestrogen receptor positive (ER+) malignancy without the concurrent administration of a medication to reduce the potential impact of raised oestrogen concentrations.
Relapse-free survival/mortality
Four studies, encompassing 464 women, reported breast cancer mortality and recurrence. The largest was a prospective non-randomized study that compared the outcome of 120 women with Stage I-III breast cancer who underwent COH with letrozole co-administration to 217 women with similar disease who declined fertility preservation treatment (Kim et al., 2016) . The mean duration of follow-up was 5.0 years (SD 2.1) in the COH group and 6.9 years (SD 3.6) in the control group. There was no significant difference between groups in breast Identification * The women included in a study by Azim et al (2007) formed a subset of the women included in a study by Kim et al (2016) . To avoid data duplication, the study by Azim et al (2007) Figure 1 Article selection process for a systematic review of the literature on women with early breast cancer undergoing controlled ovarian hyperstimulation.
cancer relapse-free survival (P = 0.61, hazard ratio 0.77 [95% CI 0.28-2.13]). In the COH group, 6/120 women (5%) experienced a recurrence compared with 12/217 women (5.5%) in the control group (P = 0.86). Of the women who underwent COH prior to surgery, 1/14 (7.0%) experienced a recurrence, compared with 5/106 (4.0%) in the post-operative group (P = 0.47).
A second prospective observational study of women with Stage 0-IIIB breast cancer compared recurrence rates in 29 women who underwent COH using tamoxifen only (12 women, 13 cycles) with a median follow-up of 418 days (SD 109); tamoxifen plus FSH (7 women, 9 cycles) with median follow-up of 609 days (SD 89); or letrozole plus FSH (11 women, 11 cycles) with median follow-up of 272 days (SD 31); with 31 women who did not undergo fertility preservation treatment forming a control group with median follow-up of 660 days (SD 71) (Oktay et al., 2005) . One woman underwent a cycle of both tamoxifen and letrozole. There was no significant difference in the recurrence rate after COH (hazard ratio 1.5; 95% CI, 0.29-7.4), with breast cancer recurrence occurring in 3/29 (10.3%) women in the COH group and in 3/31 (9.7%) women in the control group. The duration of follow-up was significantly shorter in the letrozole-IVF group (P < 0.001) as the letrozole protocol was added to the study after its commencement.
A third prospective observational study compared 43 women with an ER+ breast cancer who received COH plus tamoxifen to 27 women with an oestrogen receptor negative (ER−) breast cancer who received COH without tamoxifen, with deaths and metastatic disease recorded from a national cancer registry. Follow-up was for 3-10 years, and during this time no increased risk of cancer recurrence (2/33 (6.1%) versus 2/13 (15.4%)) or mortality (2/33 (6.1%) versus 1/13 (7.7%)) was reported in the women receiving FSH plus tamoxifen versus tamoxifen alone groups, respectively (Meirow et al., 2014) .
The final study is retrospective and reports recurrence in 2 of 24 (8.3%) women with breast cancer who underwent COH for fertility preservation during the follow-up period of 20-52 months (Ben-Haroush et al., 2011) . There was no comparison group and breast cancer stage at diagnosis was not reported.
Co-administration of an AI
Twelve studies have examined the effects of an AI administered to women with breast cancer and the results are reported in Table I . Studies reported a significant reduction in peak oestradiol concentrations with administration of letrozole (Oktay et al., 2006; Checa Vizcaino et al., 2012; Domingo et al., 2012; Revelli et al., 2013) . Peak oestradiol concentrations of 337-829 pg/ml were attained when letrozole was commenced on Days 2-3 (Oktay et al., 2005 (Oktay et al., , 2006 Azim et al., 2007; Ben-Haroush et al., 2011; Checa Vizcaino et al., 2012; Domingo et al., 2012; Lee and Oktay, 2012; Revelli et al., 2013; Turan et al., 2013; Reddy et al., 2014; Kim et al., 2016) . These levels are marginally higher than the peak oestradiol concentrations of 229-439 pg/ml that occur in natural cycle IVF (Fahy et al., 1995) . Whilst both letrozole and anastrozole are third-generation reversible AIs, they do not appear to be equipotent, with a study of 54 women receiving either letrozole or anastrozole COH terminated early when it was evident that anastrozole did not suppress oestradiol at its maximum tolerated oral dose of 10 mg daily (714 pg/ml (SD 440.83) versus 2 515.07 pg/ml (SD 1 368.52), P = 0.01) (Azim et al., 2007) .
Four studies investigated whether the co-administration of letrozole impacted the oocyte yield, with two studies encompassing 122 women reporting no change in the oocyte yield (Oktay et al., 2006; Checa Vizcaino et al., 2012) and two reporting a small but significant decrease in oocyte yield (Domingo et al., 2012; Revelli et al., 2013) . Of note, in one of the latter studies the total amount of FSH administered to the women with an ER+ breast cancer who received letrozole was significantly less than the amount administered to women with an ER− breast cancer who underwent COH without letrozole (Revelli et al., 2013) . This will have biased the finding of a decreased oocyte yield reported for women who received letrozole.
Two studies compared the GnRH agonist and hCG triggers in women undergoing COH with letrozole co-administration Reddy et al., 2014) . Neither study found a difference in peak oestradiol concentrations, although one study reported a more rapid decrease in post-trigger oestradiol concentrations with a GnRH agonist trigger . The other study reported a lower rate of mild or moderate ovarian hyperstimulation syndrome with the use of a GnRH agonist trigger. Although there was no significant difference in the total number of oocytes retrieved between groups, both studies reported significantly more mature oocytes when a GnRH agonist trigger was used compared with hCG.
Administration of tamoxifen during COH
Four studies examined the effect of tamoxifen administered to women with breast cancer (Oktay et al., 2003 (Oktay et al., , 2005 Quintero et al., 2010; Meirow et al., 2014) . These are reported in Table II . Peak oestradiol concentrations were significantly higher in women who were administered tamoxifen versus women undergoing natural cycle IVF (Oktay et al., 2003) . In the one study that reported oestrogen levels in women undergoing COH with or without tamoxifen, no significant difference in oestrogen concentration was identified (Meirow et al., 2014) . In the one study that compared tamoxifen only COH with FSH plus tamoxifen COH and FSH plus letrozole COH, significantly higher oestrogen concentrations were reported in the FSH plus tamoxifen group compared with the other two groups (Oktay et al., 2005) .
With regard to oocyte yield, one study compared natural cycle IVF with tamoxifen only IVF and reported an increased proportion of mature oocytes with the use of tamoxifen (Oktay et al., 2003) . Of the two studies that compared COH with or without the co-administration of tamoxifen, neither reported a statistical difference in oocyte yield (Quintero et al., 2010; Meirow et al., 2014) . One prospective nonrandomized study compared tamoxifen only COH with FSH plus tamoxifen COH and FSH plus letrozole COH. Tamoxifen only COH produced significantly less total oocytes (1.7 (SD 0.3)) compared with FSH plus tamoxifen (6.9 (SD 1.1)) and FSH plus letrozole 12.3 (SD 2.5) (Oktay et al., 2005) .
Discussion
Breast cancer is a complex, heterogeneous disease with differences in cell receptors, and gene mutations and methylation patterns causing variation in response to hormonal stimuli and clinically diverse behaviour. In women with an ER+ breast cancer, there is strong evidence that minimizing oestrogen exposure reduces recurrence and cancerrelated mortality, and both letrozole and tamoxifen have been shown GnRH agonist versus hCG trigger: 11.9 (SD 6.6) versus 7.4 (SD 4.9); P < 0.001
Retrospective cohort study women with breast cancer who received FSH plus letrozole COH (expansion of previously published ) pilot data). Continued to be advantageous in this context (Early Breast Cancer Trialists' Collaborative Group, 1998 , 2015 . Oestradiol can accelerate the proliferation of breast cancer cells through both oestrogen and nonoestrogen receptor modulated pathways since it promotes angiogenesis, important for tumour neovascularization (Nukamura et al., 1996; Dabrosin et al., 2003; Lincoln et al., 2003) , and stimulates the production of insulin-like growth factor 1 that has mitogenic and antiapoptotic effects on breast cancer when used long term (Christopoulos et al., 2015) . Whilst current evidence-based management of ER+ breast cancer involves long-term oestrogen minimization, it is too simplistic to claim that oestrogen always has a deleterious effect. Studies have consistently demonstrated an unchanged or improved survival rate in pregnant women (Valachis et al., 2011; Luo et al., 2014; Raphael et al., 2015) despite oestradiol concentrations of around 20 000 pg/ml arising in the third trimester (Troisi et al., 2003) .
It is not known whether the transient period of raised oestrogen concentrations during COH is harmful to women with breast cancer; however, it would be unethical to conduct such studies and a more prudent approach in such circumstances is to minimize any potential risk whenever possible.
The complexities associated with COH in women with breast cancer are not confined to women with an ER+ malignancy. Tumours may be classified as 'oestrogen receptor negative' when <10% of cells stain positive for the oestrogen receptor, although these residual cells might be of clinical significance (Harvey et al., 1999) . Receptor heterogeneity may result in ER+ cells being missed, and diagnostic false negative rates of up to 15-20% are reported (Swain, 2001) . Intracellular activities are not only mediated by the oestrogen receptor, with signalling via the G protein-coupled receptor GPR30 leading to alterations in calcium flux, production of cAMP and the activation of mitogenactivated protein kinases (Erk-1 and Erk-2) (Filardo et al., 2000; Rae and Johnson, 2005; Prossnitz et al., 2008; Mo et al., 2013) . These actions are important as they indicate that ER− breast cancers expressing GPR30 are able to utilize oestradiol to drive cellular responses (Filardo et al., 2000; Pandey et al., 2009) .
Breast cancer recurrence peaks at 18 months post-surgery, with a secondary peak at around 60 months, followed by a tapering off of recurrence that extends up to 15 years (Demicheli et al., 1996) . Definitive statements regarding the safety of COH in women with a recent diagnosis of breast cancer would require long-term and largescale studies, and these do not yet exist. The largest published study of 120 women with breast cancer having COH with letrozole (Kim et al., 2016 ) has a 5-year follow-up and provides some evidence that treatment with letrozole does not lead to a medium-term deterioration in breast cancer prognosis, providing women with some guidance as to clinical outcome when they are considering fertility preservation.
The data relating to tamoxifen co-administration during COH are less robust with only two studies including a total of 40 women who received tamoxifen during COH reporting no increased risk for recurrence or mortality (Oktay et al., 2005; Meirow et al., 2014) . Given these small numbers, firm conclusions regarding the safety of COH with tamoxifen co-administration are not possible.
A comparison of the protective effect of either tamoxifen or letrozole during COH is not possible as only one observational study of 29 women compared these medications (Oktay et al., 2005) . A metaanalysis of data from post-menopausal women reports superiority of 1.7 (SD 0.3) versus 6.9 (SD 1.1) versus 12.3 (SD 2.5); TamOnly group had significantly less oocytes than the other two groups,
TamOnly versus TamFSH versus LetFSH:
1.5 (SD 0.3) versus 5.1 (SD 1.1) versus 8.5 (SD 1.6); TamOnly group had significantly less oocytes than the other two groups, 
Continued
AIs to tamoxifen in preventing breast cancer recurrence (Early Breast Cancer Trialist's Collaborative Group, 2015) ; however, these results cannot be extrapolated to their use during COH. The studies in this review uniformly demonstrate that the administration of letrozole during COH reduces oestrogen levels without substantially reducing oocyte yield (Oktay et al., 2006; Checa Vizcaino et al., 2012; Domingo et al., 2012; Revelli et al., 2013) . Letrozole is superior to anastrozole in suppressing oestrogen level during COH (Azim et al., 2007) , a finding that is in line with breast cancer trials showing superior suppression of oestrogen concentrations with the use of letrozole (Geisler et al., 2001 (Geisler et al., , 2002 (Geisler et al., , 2008 Dixon et al., 2008) . Since tamoxifen acts on the oestrogen receptor rather than inhibiting oestrogen production, the administration of tamoxifen during COH does not lower oestrogen levels (Oktay et al., 2003) . Oocyte yield does not appear to be impacted with the co-administration of tamoxifen (Quintero et al., 2010; Meirow et al., 2014) .
The safety of letrozole was questioned in a published abstract that suggested an increased rate of locomotor malformations and cardiac anomalies in 150 babies born after letrozole was used to induce ovulation (Biljan et al., 2005) . This led to the manufacturer warning against the use of letrozole in premenopausal women. These data were never published in a peer-reviewed journal, with methodological issues including failure to report demographic and medical differences between interventional and control groups, and lack of pregnancy termination information for the control group-substantial flaws that may have influenced the measured outcomes.
Much larger studies encompassing 2707 women have not supported the finding of an increased risk to the foetus with the use of letrozole (Tulandi et al., 2006; Forman et al., 2007; Legro et al., 2014; Sharma et al., 2014) . A recent retrospective cohort study comparing 3136 natural cycles and 792 letrozole cycles confirms the finding of no increase in risk of major congenital anomalies in women treated with letrozole for IVF superovulation (1.5% versus 1.9%, natural versus letrozole cycles, P = 0.52), with a significant decrease in the miscarriage rate in women who were administered letrozole (adjusted odds ratio 0.37, 95% CI, 0.30-0.47, P < 0.001) (Tatsumi et al., 2016) .
Tamoxifen has a similar chemical structure to diethylstilbestrol (Barthelmes and Gateley, 2004) and is potentially teratogenic if administered during pregnancy (Cunha et al., 1987; Braems et al., 2011) . However, when used for ovulation induction, tamoxifen is administered prior to pregnancy and concerns regarding teratogenicity are superfluous. Tamoxifen is licensed for the purpose of ovulation induction in several countries.
The exposure of the embryo to medications differs in ovulation induction and in COH for fertility preservation, with fertilization and embryogenesis occurring in vivo in the former and in vitro in the latter. Consequently, concerns relating to teratogenicity of either letrozole or tamoxifen in the context of ovulation induction cannot be extrapolated to being applicable in the context of fertility preservation.
The use of a GnRH agonist trigger is recommended for women with breast cancer undergoing COH for several reasons: it results in a faster decline in oestradiol concentrations following oocyte collection ; it is associated with a reduced rate of ovarian hyperstimulation (Babayof et al., 2006; Griesinger et al., 2007; Engmann et al., 2008; Melo et al., 2009; Reddy et al., 2014; Youssef et al., 2014) ; and it results in a greater mature oocyte yield (Humaidan et al., 2005; reduction in pregnancy or live birth rates in cryopreservation cycles. The reduced ongoing pregnancy and live birth rates reported after the use of a GnRH agonist trigger in fresh transfer cycles (Humaidan et al., 2005; Kolibianakis et al., 2005; Griesinger et al., 2006; Youssef et al., 2014) are believed to be secondary to an endometrial receptivity defect (Humaidan et al., 2011) as they are not seen in cryopreservation or donor oocyte cycles (Melo et al., 2009; Youssef et al., 2014) . As fertility preservation always utilizes cryopreservation, the reduction in pregnancy rate seen in GnRH agonist triggered cycles is not relevant. Alterations in circulating progesterone, vascular endothelial growth factor (VEGF) and androgen concentrations may occur in addition to the oestradiol rise seen during COH. The elevated VEGF concentrations that occur during COH (Licht et al., 2001; Bersinger et al., 2014) are of concern as VEGF is a key mediator in angiogenesis (Yang et al., 2015) and VEGF inhibitors have been reported to improve response rate and progression-free survival in some breast cancers (Cao et al., 2015; Tonissi et al., 2015) . The impact of raised VEGF levels during COH on breast cancer is currently unknown.
Up to 70-80% of breast cancers are androgen receptor positive (AR+) (Finlay-Schultz , 2015) , and since AIs inhibit the conversion of androgens to oestrogens, it is likely that androgen levels increase during treatment with letrozole (Gallicchio et al., 2011) . It is unclear whether the androgenic effect on breast cancer cells is predominantly proliferative or anti-proliferative (Collins et al., 2011) . The AR may inhibit ERα activity in oestradiol-stimulated breast cancer cell proliferation (Peters et al., 2009) and rising androgen concentrations during COH with letrozole administration may not be harmful.
Conclusion
The existing literature concerning COH for fertility preservation in women with breast cancer is limited by its observational nature, small patient numbers and relatively short duration of follow-up. The difficulty in undertaking RCTs in this patient population is recognized. Current information suggests that COH with letrozole co-administration does not cause a marked short-term deterioration in cancer prognosis and reduces oestradiol concentrations without substantially decreasing the total or mature oocyte yield. A prudent approach to fertility preservation using COH in a woman with breast cancer would be to administer letrozole (5 mg/day) from Day 2 of stimulation, with the subsequent use of a GnRH agonist trigger. The administration of tamoxifen during COH may also be beneficial, but the evidence base is less robust. Women with ER− breast cancer may also benefit from a similar treatment regime.
